• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Abivax SA

    4/20/26 4:07:48 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVX alert in real time by email
    6-K 1 abivax-6xkpreparatorydocum.htm 6-K Abivax - 6-K (Preparatory Documents PR) (Apr 2026)
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 6-K
    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
    SECURITIES EXCHANGE ACT OF 1934
    For the month of April 2026
    Commission File Number: 001-41842
    Abivax SA
    (Translation of registrant’s name into English)
    7-11 boulevard Haussmann
    75009 Paris, France
    +33 (0) 1 53 83 08 41
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
    F.
    Form 20-F [ X ] Form 40-F [ ]
    On April 20, 2026, Abivax SA (the “Registrant”) published a press release entitled “Annual Ordinary and
    Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents.” A copy of the press
    release is filed as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.
    The inclusion of any website address herein, including in any exhibit attached hereto, is intended to be an inactive
    textual reference only and not an active hyperlink. The information contained in, or that can be accessed through,
    such website is not part of this Form 6-K nor is it incorporated herein.
    Incorporation by Reference
    This Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the
    Registrant’s registration statements on Form F-3 (File No. 333-283336 and 333-288884) and Form S-8 (File No.
    333-286069 and 333-294544) and to be part thereof from the date on which this Report is filed, to the extent not
    superseded by documents or reports subsequently filed.
    Exhibit Index
    Exhibit 99.1
    Press release, dated April 20, 2026
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
    signed on its behalf by the undersigned, thereunto duly authorized.
    Abivax SA
    (Registrant)
    Date: April 20, 2026
    /s/ Marc de Garidel
    Marc de Garidel
    Chief Executive Officer
    Get the next $ABVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVX

    DatePrice TargetRatingAnalyst
    6/2/2026$90.00Buy → Hold
    Jefferies
    6/2/2026$90.00Underperform → Neutral
    Wedbush
    3/16/2026$160.00Buy
    Jefferies
    2/24/2026$110.00Outperform
    Wedbush
    11/24/2025Buy
    Truist
    11/6/2025$176.00Outperform
    Wolfe Research
    10/13/2025$142.00Overweight
    Barclays
    7/23/2025$71.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ABVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Abivax SA downgraded by Jefferies with a new price target

    Jefferies downgraded Abivax SA from Buy to Hold and set a new price target of $90.00

    6/2/26 8:18:19 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax SA upgraded by Wedbush with a new price target

    Wedbush upgraded Abivax SA from Underperform to Neutral and set a new price target of $90.00

    6/2/26 8:17:12 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Abivax SA with a new price target

    Jefferies initiated coverage of Abivax SA with a rating of Buy and set a new price target of $160.00

    3/16/26 8:36:55 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    SEC Filings

    View All

    SEC Form 6-K filed by Abivax SA

    6-K - Abivax S.A. (0001956827) (Filer)

    6/2/26 6:01:03 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Abivax SA

    6-K - Abivax S.A. (0001956827) (Filer)

    5/22/26 4:12:54 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Abivax SA

    6-K - Abivax S.A. (0001956827) (Filer)

    5/20/26 4:47:26 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)Both 25 mg and 50 mg obefazimod met all key secondary endpoints, demonstrating robust and clinically meaningful efficacy results across multiple measures of disease controlObefazimod demonstrated a favorable safety profile over the 44-week maintenance trial (N=580), with no new safety signalsRecently reported Phase 2a/2

    6/1/26 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

    DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially

    5/28/26 8:35:00 AM ET
    $ABVX
    $ORKA
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

    Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat ("ITT") analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis ("UC") patients treated with obefazimodFollowing two to four years of open-label treatment with 50 mg, 130 patients de-escalated to 25 mg, and at week 144, 68% (88/130) were in clinical remission and 80% (104/130) completed 144 weeks of treatmentPatients in Study 108 were treated with obefazimod for up to seven years, wit

    5/22/26 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Leadership Updates

    Live Leadership Updates

    View All

    Abivax Announces Results of its June 6, 2025 Annual General Meeting

    Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

    6/11/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

    4/22/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

    11/13/24 4:01:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Financials

    Live finance-specific insights

    View All

    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

    Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)Both 25 mg and 50 mg obefazimod met all key secondary endpoints, demonstrating robust and clinically meaningful efficacy results across multiple measures of disease controlObefazimod demonstrated a favorable safety profile over the 44-week maintenance trial (N=580), with no new safety signalsRecently reported Phase 2a/2

    6/1/26 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

    10/6/25 4:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

    10/5/25 11:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abivax SA

    SC 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/24 9:09:55 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Abivax SA

    SC 13G - Abivax S.A. (0001956827) (Subject)

    4/19/24 7:09:50 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care